An enhanced view
of cancer.

On Target Laboratories’ fluorescent markers are being developed to bind to cancerous tissue, enabling surgeons to see the lesions as they operate.

A complete surgical resection is the most important objective of cancer surgery. Yet the methods currently used to identify malignant tissue are limited – skilled surgeons often rely only on preoperative imaging and real time visual and tactile cues.

There is an unmet need for greater certainty when assessing the location and full extent of cancerous tissue while operating.

ON TARGET LABORATORIES’s fluorescent markers bind to cancerous tissue, enabling surgeons to see the cancerous lesions as they operate.

On Target’s fluorescent markers are comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to the receptors overexpressed on cancer cells. These markers are designed to illuminate the cancerous lesions, lighting the way for the resection of malignant tissue.

Our novel intraoperative markers are creating an entirely new category of tools in the surgical resection of cancer. The ultimate goal — surgeons feeling even more confident in the pursuit of a complete surgical resection for their patients.

Clinical trials are underway in more than a dozen centers to evaluate our portfolio of fluorescent markers. Clinical trials are underway in more than a dozen centers to evaluate our portfolio of fluorescent markers.

Development Focus

We’re developing technology where it’s needed most.

Lung, ovarian, prostate, and colorectal cancers alone make up nearly 72% of inpatient oncology procedures in the US1. On Target is developing intraoperative targeted fluorescent markers in multiple cancer types. The potential of this technology solidifies our commitment to our mission of making cancer visible during surgery so it can be removed more completely.

1. Orosco, Ryan, et al. Positive Surgical Margins in the 10 Most Common Solid Cancers. Nature. 2018; 8:5686. doi:10.1038/s41598-018-23403-5

 

Clinical Research

Clinical trials are underway in more than a dozen centers to evaluate On Target Laboratories’ portfolio.

Ovarian Cancer Phase 3 Study

This study is designed to evaluate the efficacy of pafolacianine sodium injection (OTL38) in combination with near-infrared fluorescence imaging to detect additional ovarian cancer lesions not detected by palpation and visualization under normal light during surgery

Learn More

Lung Cancer Phase 3 Study (ELUCIDATE)

This study aims to assess the efficacy, safety, and tolerability of pafolacianine sodium injection and near-infrared fluorescence imaging at identifying pulmonary nodules within the operating theater

Learn More

Prostate Cancer Phase 1/2a Study

This study is to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent marker, for the intraoperative imaging of prostate cancer

Learn more
Brand Strategy By Assembly
Developed By Alchemy + Aim